{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-021284","form_type":"8-K","ticker":"AURA","cik":"0001501796","company_name":"Aura Biosciences, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.095203+00:00","generated_at":"2026-06-15T04:00:41.886735+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aura Biosciences reports Q1 2023 net loss of $17.5M; FDA backs Phase 3 trial design for choroidal melanoma","bullets":["Cash and marketable securities $173.5M as of March 31, 2023; cash runway into 2025.","Net loss $17.5M for Q1 2023 vs $12.8M in Q1 2022; R&D expense $14.4M (up from $8.3M).","FDA Type C meeting supports global Phase 3 trial (≈100 patients, 2:1:2 randomized) for early-stage choroidal melanoma.","Phase 2 enrollment complete; updated interim data expected 2H 2023; Phase 1 NMIBC data also due 2H 2023.","Appointed Patrick Nealon as SVP, Clinical Development Operations to lead late-stage development."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-021284","json":"https://secwatch.observer/filing/0000950170-23-021284.json","markdown":"https://secwatch.observer/filing/0000950170-23-021284.md","text":"https://secwatch.observer/filing/0000950170-23-021284.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501796/000095017023021284/0000950170-23-021284-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501796/000095017023021284/aura-20230511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:00:41.886735+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"83a5c6c5821147046cf7985d867e3318bfab5264","claim":"Aura Biosciences, Inc. reported the quarter ended March 31, 2023 results: net income $17.5 million.","evidence_excerpt":"On May 11, 2023, Aura Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501796/000095017023021284/0000950170-23-021284-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Net income","value":"$17.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}